Search Bar & Filters
Found 47 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.
Actively Recruiting
Researchers are studying the safety and performance of the LEGION Medial Stabilized insert used in total knee arthroplasty TKA for patients with degenerative joint disease such as osteoarthritis, post-traumatic arthritis, or inflammatory arthritis. This observational study includes both prospective and retro-prospective participants and aims to provide long-term evidence to support product registration worldwide. The study involves three groups receiving different LEGION MS insert combinations with tibia and femoral components Cemented CoCr, Cemented Oxinium, and Cementless options. Participants will be followed for 10 years after their primary knee replacement surgery to monitor outcomes related to the implant. During the study, participants will undergo regular assessments including the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement KOOS JR, Oxford Knee Score, Forgotten Joint Score, and EuroQol Five-Dimensional EQ-5D-5L questionnaires at multiple timepoints from 6 weeks up to 10 years post-surgery. Implant survivorship will be tracked at intervals up to 10 years, with all participants consenting to follow-up visits and outcome reporting to evaluate long-term device safety and effectiveness.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a prospective, 180-day controlled study to evaluate the safety and effectiveness of the Thermage FLX System, a radiofrequency device, for improving lines, wrinkles, and skin laxity in adults aged 30 to 60 years. The study aims to demonstrate that treatment with the Thermage FLX System is superior to no treatment in improving skin appearance on the neck, abdomen, upper arms, and face. This multicenter trial enrolls 164 participants across sites in North America and China. Participants are randomly assigned to receive treatment with the Thermage FLX device either at day 1 or day 90, or to an untreated control group. The Thermage FLX System is a monopolar radiofrequency device used in non-invasive dermatological procedures targeting mild-to-moderate skin laxity and wrinkles. The study includes a 6-month 26-week period during which safety, tolerability, and improvements in skin appearance are evaluated. During the study, participants undergo assessments at baseline and follow-up visits to monitor changes in skin lines, wrinkles, and laxity using standardized scales. Safety and tolerability are carefully evaluated throughout the study. Participants must comply with study instructions, attend scheduled visits, and avoid other cosmetic procedures on treatment areas during the trial. The primary outcome is measured at 90 days, with secondary assessments at 180 days.
Actively Recruiting
This research aims to evaluate whether participants who have previously taken donanemab experience clinical benefits when receiving annual doses. The study focuses on individuals with Alzheimer disease, dementia, and amyloid plaque conditions, investigating the effects of continued treatment over a period of up to 2.5 years with six visits. The trial is sponsored by Eli Lilly and Company and is conducted as a randomized, double-blind, phase 3 clinical trial. Participants are assigned to receive either donanemab or a placebo, both administered intravenously. The study follows a parallel design where each participant receives one of the two treatments. The annual dosing schedule spans up to 2.5 years, with visits planned throughout this period to monitor participants. This includes assessments of cognitive function, brain amyloid plaque levels via PET scans, plasma biomarkers, and drug concentration measurements. During the study, participants will undergo evaluations including the Clinical Dementia Rating - Sum of Boxes CDR-SB, Cognitive Function Index CFI, Florbetapir F 18 PET scans, and plasma phosphorylated tau measurements. Pharmacokinetics of donanemab will be assessed at baseline, week 52, and week 104. The study involves six visits over the entire duration, with safety and clinical benefit monitored carefully. Participation lasts up to 2.5 years, allowing comprehensive observation of treatment effects.
Actively Recruiting
Researchers are evaluating the safety and effects of the medicine Mevrometostat for treating RelapsedRefractory Small Cell Lung Cancer SCLC, Castration Resistant Prostate Cancer CRPC, and Follicular Lymphoma FL. This Phase 1 open-label study includes three parts, with Parts 1 and 2 closed for enrollment. Part 3, currently open, focuses on men with CRPC who have progressed after prior treatment. The study aims to understand how the study medicine behaves in the body and its impact on cancer. Participants in Part 3 receive Mevrometostat andor Enzalutamide. The study has two substudies a Bioequivalence BE substudy comparing two formulations of Mevrometostat, and a Drug-Drug Interaction DDI substudy with two cohorts. The BE substudy involves three single doses of Mevrometostat. The DDI substudy Cohort 1 takes Mevrometostat andor Itraconazole, and Cohort 2 combines Mevrometostat, Enzalutamide, and Itraconazole. After assessment phases, participants enter maintenance, taking Mevrometostat twice daily and Enzalutamide once daily until disease progression. Participants will visit the study center for dosing and monitoring, including evaluations of side effects, blood tests, and disease progression. The study measures dose-limiting toxicities, overall safety, and preliminary effectiveness using disease-specific criteria. Pharmacokinetics and patient-reported outcomes are also assessed at specific times. The study lasts approximately two years after the first participants visit, aiming to provide detailed safety and efficacy information.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effects of ORX750 in adults with Narcolepsy Type 1 NT1, Narcolepsy Type 2 NT2, and Idiopathic Hypersomnia IH. These rare conditions cause excessive daytime sleepiness and affect daily activities such as school, work, and driving. The study aims to understand how ORX750, which mimics the brain protein orexin that helps maintain wakefulness, impacts sleepiness and other symptoms in these conditions. Participants will receive either ORX750 capsules or matching placebo capsules in a randomized, double-blind setup. The study assesses multiple groups those with NT1, NT2, and IH. The treatment and monitoring will occur over a period of up to 35 days, including evaluation of plasma drug levels and sleepiness measures. During the study, participants will undergo safety assessments including monitoring for adverse events, laboratory tests, vital signs, ECGs, and suicidal ideation screening up to day 35. Researchers will also measure sleepiness using the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale. The total study duration for each participant is about five weeks, with careful observation of how the body processes ORX750 and its effects on daytime alertness.
Actively Recruiting
Researchers are evaluating a drug called sigvotatug vedotin SGN-B6A alone and in combination with pembrolizumab, with or without chemotherapy, to assess its safety and effects in people with advanced solid tumors. This Phase 1 study aims to determine the side effects and whether sigvotatug vedotin works to treat various solid tumors including lung, head and neck, breast, esophageal, skin, pancreatic, bladder, cervical, gastric, and ovarian cancers. The study is divided into four parts to explore dosage, safety, and combination treatments. Participants may receive sigvotatug vedotin alone or combined with pembrolizumab, sometimes alongside chemotherapy drugs carboplatin or cisplatin, depending on the study part. Part A focuses on finding the right dose of sigvotatug vedotin. Part B uses this dose to further test safety and effectiveness. Parts C and D study the drug combined with pembrolizumab and possibly chemotherapy in different tumor types and treatment settings, including people who have not previously received treatment. Treatments are given intravenously, with pembrolizumab administered every 3 or 6 weeks and chemotherapy every 3 weeks. During the study, participants undergo tumor biopsies, clinical evaluations, and monitoring for side effects, including blood tests and safety assessments. Researchers track adverse events, lab abnormalities, and dose-limiting toxicities up to 30-37 days after treatment, with some follow-up extending up to 3 years. They also measure tumor response using standard criteria and monitor survival and drug levels in the body. Participants will have regular visits for treatment and assessments throughout the study duration, which may last several years.
Actively Recruiting
Researchers are evaluating the safety and tolerability of TAK-861 in people with narcolepsy type 1 NT1. This study focuses on participants who have already been exposed to TAK-861 doses in previous clinical trials. The goal is to monitor how TAK-861 affects symptoms such as excessive daytime sleepiness and cataplexy episodes over a long period. All participants in this trial will receive TAK-861 tablets. Those who previously received a placebo will be randomly assigned to one of the TAK-861 dose groups. The study is a long-term extension conducted worldwide and is expected to last approximately five years or until the product is approved or the study is stopped. Participants may switch doses as needed and will attend multiple clinic visits, some of which can be done at home. Throughout the trial, participants will be regularly assessed for safety by tracking any treatment-emergent adverse events. Researchers will also measure changes in sleep latency, sleepiness scores, and cataplexy rates compared to baseline data from earlier trials. Follow-up assessments will take place four weeks after the final dose to monitor ongoing effects and ensure participant safety.
Actively Recruiting
Researchers are evaluating the safety and tolerability of valemetostat combined with darolutamide in adult males with Metastatic Castration Resistant Prostate Cancer mCRPC. This phase 1 trial aims to understand how these treatments work together in participants who have evidence of disease progression and metastatic spread, while continuing androgen deprivation therapy. The study is sponsored by Daiichi Sankyo and focuses on participants who have prior therapy with androgen receptor pathway inhibitors. Participants will receive valemetostat at escalating doses alongside a standard dose of darolutamide. The trial includes a dose escalation part where dosing is carefully increased, followed by a dose expansion part with two or more dose levels of valemetostat combined with darolutamide. Treatment cycles last 28 days, with valemetostat dosing monitored closely during the initial cycle and repeated in subsequent cycles. Participants will undergo assessments from screening through up to approximately 5 years, including monitoring for dose-limiting toxicities, treatment-emergent adverse events, and prostate-specific antigen PSA responses. Additional evaluations include radiographic progression, overall survival, and time to symptomatic skeletal events. Blood samples will be collected to measure plasma concentrations of the study drugs. Safety and efficacy will be closely tracked throughout the study duration.
1-10 of 47
1